)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Altamira Therapeutics
Altamira Therapeutics (CYTO) investor relations material
Altamira Therapeutics H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2025 earnings summary31 Mar, 2026
Executive summary
Expanded nucleic acid delivery business with new applications, including GenePhore for DNA delivery and further development of the xPhore platform.
Advanced plans for the spin-off of the nucleic acid delivery business and continued strategic repositioning.
Achieved milestones in associate Medica's Bentrio nasal spray, including EU MDR clearance and China marketing approval.
Financial highlights
Total operating loss from continuing operations decreased to $4.4 million in 2025 from $6.9 million in 2024.
Research and development expenses fell to $2.0 million in 2025 from $3.7 million in 2024; G&A expenses decreased to $2.6 million from $3.2 million.
Net finance income of $1.2 million in 2025 versus a net finance expense of $0.8 million in 2024.
Net loss for 2025 was $3.0 million, improved from $8.5 million in 2024; loss per share $0.55 vs. $2.99.
Shareholders' equity was $3.0 million at year-end 2025, down from $6.6 million at year-end 2024.
Outlook and guidance
Operating expenses expected to decrease significantly in 2026 following the planned spin-off and SEC deregistration.
Financial guidance will be updated as material new information becomes available.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Altamira Therapeutics
- Peptide-based RNA delivery platforms target extrahepatic diseases with strong clinical potential.CYTO
Corporate presentation31 Mar 2026 - RNA delivery advances, Bentrio expansion, and lower net loss highlight H1 2024.CYTOH1 202420 Jan 2026
- Biotech seeks up to $4.2M via flexible share and warrant offering, facing high risk and dilution.CYTORegistration Filing29 Nov 2025
- Biotech seeks $4.2M via share/warrant offering to fund RNA delivery, facing high dilution and risk.CYTORegistration Filing29 Nov 2025
- RNA delivery platform developer launches high-risk, no-minimum best efforts equity offering.CYTORegistration Filing29 Nov 2025
- RNA delivery advances, asset monetization, and spin-off plans follow Nasdaq delisting.CYTOH2 202425 Nov 2025
- Operating loss dropped 32.9% as RNA delivery advanced and ATAG spin-off preparations continued.CYTOH1 202523 Nov 2025
- Proprietary RNA delivery platforms target major unmet needs in cancer and inflammation.CYTOCorporate Presentation13 Jun 2025
- Proprietary RNA delivery platform targets major unmet needs in oncology and inflammation.CYTOCompany Presentation6 Jun 2025
Next Altamira Therapeutics earnings date
H1 202628 Aug, 2026
Altamira Therapeutics
Next Altamira Therapeutics earnings date
H1 202628 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage